Evidence map›Paper›PMID 40449553›Full record

Trial reportJNCI cancer spectrum2025

General practitioner-led vs surgeon-led colon cancer survivorship care: a randomized clinical trial.

Julien A M Vos, Laura A M Duineveld, Thijs Wieldraaijer, Jan Wind, Wim B Busschers, Edanur Sert, Irma M Verdonck-de Leeuw, Henk C P M van Weert, Kristel M van Asselt

Abstract readRandomized Controlled TrialMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Julien A M VosDepartment of General Practice, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-3383-8171
Laura A M DuineveldDepartment of General Practice, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-4780-9937
Thijs WieldraaijerDepartment of General Practice, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.
Jan WindDepartment of General Practice, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.
Wim B BusschersDepartment of General Practice, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-3393-9511
Edanur SertDepartment of General Practice, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.
Irma M Verdonck-de LeeuwDepartment of Otolaryngology-Head and Neck Surgery, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Henk C P M van WeertDepartment of General Practice, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-6370-4724
Kristel M van AsseltDepartment of General Practice, Amsterdam UMC, location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0001-9679-2177

Funding

KWF KankerbestrijdingStichting Alpe d'HuZes BMA 5954
6 · The paper itself

Abstract

The randomized controlled I CARE (Improving Care After colon canceR treatment in the Netherlands) trial evaluated the impact of general practitioner-led vs surgeon-led survivorship care on quality of life (QoL) in colorectal cancer survivors, alongside the effect of the eHealth application Oncokompas. The trial was conducted in 8 hospitals and 225 general practices across the Netherlands, including 303 patients who underwent surgery for stage I-III colon cancer or rectosigmoid carcinoma. Patients were randomly assigned into 4 groups: surgeon-led care, surgeon-led care with Oncokompas, general practitioner-led care, and general practitioner-led care with Oncokompas. QoL was assessed at multiple time points over 60 months. At 60 months, no clinically relevant differences in QoL were found between general practitioner-led and surgeon-led care (difference in summary score = -0.5, 95% CI = -1.6 to 0.5) or with Oncokompas (difference = 0.8, 95% CI = 0.0 to 1.6). In conclusion, neither general practitioner involvement nor access to Oncokompas led to clinically relevant improvements in long-term QoL. Survivorship care can be tailored to preferences. Netherlands Trial Register; NTR4860.

Indexed as

Cancer SurvivorsColonic NeoplasmsGeneral PractitionersQuality of LifeSurgeonsAgedAged, 80 and overFemaleHumansMaleMiddle AgedNetherlandsSurvivorshipTelemedicine

Identifiers

PMID40449553
PMCPMC12163231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.